陕西康惠制药股份有限公司第六届董事会第六次会议决议公告

Group 1 - The company held its sixth board meeting on January 14, 2026, with all nine directors present, and the meeting was deemed legally valid [2][4] - The board approved the proposal regarding the occurrence of related party transactions for 2025 and the expected related party transactions for 2026, which will be submitted for shareholder approval [3][4] - The board also approved the proposal to convene the first extraordinary general meeting of shareholders in 2026, scheduled for January 30, 2026 [5][6] Group 2 - The company and its wholly-owned subsidiary, Beijing Kanghui Zhichuang Technology Co., Ltd., are expected to engage in daily related party transactions based on operational needs, adhering to principles of fairness and reasonableness [10][17] - Independent directors and the audit committee reviewed and approved the related party transaction proposal, confirming that it would not harm the interests of the company or its shareholders [11][12] - The expected related party transactions for 2026 will involve sales of pharmaceutical products and provision of technical services, with pricing based on market standards [16][17] Group 3 - The first extraordinary general meeting of shareholders will utilize a combination of on-site and online voting, with specific details provided for the voting process [20][21] - Shareholders must register for the meeting by January 29, 2026, and can participate either in person or through a proxy [29][32] - The meeting is expected to last half a day, and attendees are responsible for their own expenses [34]